BTIG has increased its price target for United Therapeutics from $728 to $768, maintaining a Buy rating. This adjustment suggests a potential upside of 27.7% from the stock's closing price on November 3, 2026, reflecting a positive outlook on the company's market position.
Investment firm BTIG has raised its price target for United Therapeutics (UTHR) from $728 to $768, while reiterating a 'Buy' rating. This 5.5% increase in the target price signals a positive outlook on the company's market position and implies a potential upside of approximately 27.7% from the stock's closing price on November 3, 2026. For traders, this could lead to short-term positive sentiment and increased buying interest in UTHR, as analysts' price target adjustments often influence investor perception. The long-term implications depend on whether the company's fundamentals and future performance align with BTIG's optimistic valuation, but for now, it presents an opportunity for those looking for upward momentum.